Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-25 5:00 pm Purchase |
2025-07-18 | 13G | Contineum Therapeutics, Inc. Class A Common Stock CTNM |
RA Capital Management, L.P. | 2,122,000 9.900% |
2,122,000 (New Position) |
Filing History |
| 2025-06-30 5:05 pm Purchase |
2025-06-26 | 13D | Cidara Therapeutics, Inc. CDTX |
RA Capital Management, L.P. | 3,365,523 15.800% |
2,272,727 (+207.97%) |
Filing History |
| 2025-06-27 4:16 pm Purchase |
2025-06-25 | 13D | Vor Biopharma Inc. VOR |
RA Capital Management, L.P. | 39,739,850 31.800% |
30,000 (+0.08%) |
Filing History |
| 2025-06-06 4:50 pm Purchase |
2025-06-04 | 13D | Tyra Biosciences, Inc. TYRA |
RA Capital Management, L.P. | 11,899,788 22.400% |
1,214,898 (+11.37%) |
Filing History |
| 2025-05-19 5:46 pm Sale |
2025-05-15 | 13D | iTeos Therapeutics, Inc. ITOS |
RA Capital Management, L.P. | 2,134,806 4.900% |
-2,028,470 (-48.72%) |
Filing History |
| 2025-05-15 4:59 pm Sale |
2025-03-31 | 13G | Kura Oncology, Inc. KURA |
RA Capital Management, L.P. | 4,004,610 4.900% |
-364,388 (-8.34%) |
Filing History |
| 2025-05-15 4:58 pm Purchase |
2025-03-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS |
RA Capital Management, L.P. | 11,063,125 9.900% |
187,671 (+1.73%) |
Filing History |
| 2025-05-15 4:58 pm Purchase |
2025-03-31 | 13G | GH Research PLC GHRS |
RA Capital Management, L.P. | 6,944,648 11.200% |
257,959 (+3.86%) |
Filing History |
| 2025-05-15 4:57 pm Purchase |
2025-03-31 | 13G | Geron Corporation GERN |
RA Capital Management, L.P. | 63,988,106 9.900% |
668,553 (+1.06%) |
Filing History |
| 2025-05-15 4:56 pm Purchase |
2025-03-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 1,328,578 9.900% |
176,566 (+15.33%) |
Filing History |
| 2025-05-15 4:56 pm Purchase |
2025-03-31 | 13G | Dyne Therapeutics, Inc. DYN |
RA Capital Management, L.P. | 9,714,392 8.500% |
3,333,248 (+52.24%) |
Filing History |
| 2025-05-15 4:55 pm Purchase |
2025-03-31 | 13G | Surrozen, Inc. SRZN |
RA Capital Management, L.P. | 867,418 9.900% |
543,756 (+168.00%) |
Filing History |
| 2025-05-15 4:55 pm Unchanged |
2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH |
RA Capital Management, L.P. | 2,866,733 8.900% |
0 (Unchanged) |
Filing History |
| 2025-05-15 4:53 pm Sale |
2025-03-31 | 13G | Chimerix, Inc. CMRX |
RA Capital Management, L.P. | 0 0.000% |
-8,800,000 (Position Closed) |
Filing History |
| 2025-05-15 4:53 pm Unchanged |
2025-03-31 | 13G | UroGen Pharma Ltd. URGN |
RA Capital Management, L.P. | 3,206,271 7.000% |
0 (Unchanged) |
Filing History |
| 2025-05-15 4:52 pm Sale |
2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC |
RA Capital Management, L.P. | 0 0.000% |
-4,878,000 (Position Closed) |
Filing History |
| 2025-05-15 4:51 pm Purchase |
2025-03-31 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 12,964,491 9.900% |
314,763 (+2.49%) |
Filing History |
| 2025-05-15 4:51 pm Sale |
2025-03-31 | 13G | Bright Minds Biosciences Inc. DRUG |
RA Capital Management, L.P. | 206,427 2.900% |
-254,402 (-55.21%) |
Filing History |
| 2025-05-15 4:49 pm Purchase |
2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX |
RA Capital Management, L.P. | 1,094,407 9.900% |
127,108 (+13.14%) |
Filing History |
| 2025-05-15 4:49 pm Sale |
2025-03-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 6,011,112 7.100% |
-1,766,830 (-22.72%) |
Filing History |